Victoria Holiday, MD
Neurology · Louisville, KYNPI 1477879815
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 39.5% of the total.
Across 52 payments — averaging $108.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Boston Scientific$756
- MDD US Operations, LLC$265
- Teva Pharmaceuticals USA, Inc.$125
- Amneal Pharmaceuticals LLC$120
- plus $403 from 6 others
Across 5 payments — averaging $1514.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$8K
What the payments were for
- Travel & lodging$3,08655%
- Food & beverage$2,53945%
- Education$281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $2,233 |
| Abbott | 9 | $1,751 |
| Boston Scientific | 7 | $756 |
| MDD US Operations, LLC | 3 | $265 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Amneal Pharmaceuticals LLC | 1 | $120 |
| Neurocrine Biosciences, Inc. | 1 | $120 |
| Kyowa Kirin, Inc. | 1 | $112 |
| Acadia Pharmaceuticals Inc | 1 | $109 |
| SK Life Science, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,653 in reported general payments places this provider in the 65th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 55 | $185,788 |
| Austedo XrDeutetrabenazine | 14 | $184,554 |
| NuplazidPimavanserin Tartrate | 22 | $116,273 |
| RytaryCarbidopa/Levodopa | 45 | $88,325 |
| DuopaCarbidopa/Levodopa | 12 | $75,070 |
| InbrijaLevodopa | 13 | $60,034 |
| NourianzIstradefylline | 18 | $35,757 |
| NeuproRotigotine | 12 | $20,447 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 441 | $19,193 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 99 | $10,958 |
| Pramipexole ErPramipexole Di-Hcl | 17 | $7,364 |
| Rasagiline Mesylate | 31 | $7,277 |
| Entacapone | 42 | $6,445 |
| AmantadineAmantadine Hcl | 69 | $3,813 |
| RivastigmineRivastigmine Tartrate | 31 | $3,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $265 | $185,78855 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $125 | $184,55414 claims |
| Acadia Pharmaceuticals IncNuplazid | $109 | $116,27322 claims |
| Amneal Pharmaceuticals LLCRytary | $120 | $88,32545 claims |
| Kyowa Kirin, Inc.Nourianz | $112 | $35,75718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
- Jeffrey FrankLouisville$181K
- Mohammad AlsorogiLouisville$111K
- Tad SeifertLouisville$99K
- Michael SweeneyLouisville$71K
- Michael SowellLouisville$60K
- David RobertsonLouisville$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.